ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v15i1.1844ppharm-1594Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWТеоретические основы и реальные результаты: обзор материалов по вакцинопрофилактике пневмококковой инфекции в миреTheoretical Background and Real Results: A Data Review on Vaccine Prevention of Pneumococcal Infection in the WorldНамазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва

Moscow

ФедосеенкоМ. В.FedoseenkoMarina V.

Федосеенко Марина Владиславовна - кандидат медицинских наук, старший научный сотрудник отдела профилактической педиатрии, отдела стандартизации и клинической фармакологии НМИЦ здоровья детей.

119991, Москва, Ломоносовский пр-т, д. 2/62, тел.: +7 (499) 134-20-92

Moscow

titovamarina@mail.ruВишнёваЕ. А.VishnevaElena A.

Москва

Moscow

СелимзяноваЛ. Р.SelimzianovaLilia R.

Москва

Moscow

ЧемакинаД. С.ChemakinaDaria S.

Москва

Moscow

Национальный медико-исследовательский центр здоровья детей; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияNational Medical Research Center of Children’s Health; Pirogov Russian National Research Medical UniversityRussian FederationНациональный медико-исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian Federation2018270220181515874Copyright © Намазова-Баранова Л.С., Федосеенко М.В., Вишнёва Е.А., Селимзянова Л.Р., Чемакина Д.С., 20182018Намазова-Баранова Л.С., Федосеенко М.В., Вишнёва Е.А., Селимзянова Л.Р., Чемакина Д.С.Namazova-Baranova L.S., Fedoseenko M.V., Vishneva E.A., Selimzianova L.R., Chemakina D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1594

Настоящий обзор, составленный с целью обобщения взглядов на эпидемиологию пневмококковой инфекции и возможности наиболее эффективных мер борьбы с ее распространением, объединяет результаты исследований российских и международных групп, полученные в ходе изучения вопросов вакцинопрофилактики пневмококковой инфекции. В предыдущем обзоре важнейших показателей эффективности вакцинации против пневмококковой инфекции были определены основные подходы к оценке результативности вакцинации против пневмококковой инфекции, а также систематизированы научные данные мирового опыта применения пневмококковых конъюгированных вакцин. Настоящий обзор нацелен на суммирование доказательств эффективности и воздействия пневмококковых конъюгированных вакцин на ключевые «конечные точки» эпидемиологического процесса пневмококковой инфекции.

The article presents the review aimed at summarizing the opinions on the epidemiology of pneumococcal infection and the most effective measures for its prevention. The review combines the results of the trials conducted by Russian and international groups who analysed vaccine prophylaxis of pneumococcal infection. In the previous review on the most important indicators of the effectiveness of vaccination against pneumococcal infection, the main approaches to the assessment of the effectiveness of vaccination against pneumococcal infection were identified, and the academic data on the global experience of pneumococcal conjugate vaccination was systematized. This review results in cumulation of evidence for the efficacy and impact of pneumococcal conjugate vaccines on the key «end points» of the epidemiological process of pneumococcal infection.

пневмококковые конъюгированные вакциныэффективность вакцинациинациональная программа иммунизацииpneumococcal conjugate vaccineeffectiveness immunizationNational Immunization Schedule«Пфайзер», компанияReferencesБрико Н.И., Лобзин Ю.В., Баранов А.А., и др. Оценка эффективности вакцинации: основные подходы и спорные вопросы // Педиатрическая фармакология. — 2014. — Т.11. — №4 — С. 8–15. [Briko NI, Lobzin YuV, Baranov AA, et al. Assessment of vaccination program effectiveness: basic approaches and issues. Pediatric pharmacology. 2014;11(4):8–15. (In Russ).] doi: 10.15690/pf.v11i4.1057.Брико Н.И., Лобзин Ю.В., Баранов А.А., и др. Оценка эффективности вакцинации: основные подходы и спорные вопросы // Педиатрическая фармакология. — 2014. — Т.11. — №4 — С. 8–15. [Briko NI, Lobzin YuV, Baranov AA, et al. Assessment of vaccination program effectiveness: basic approaches and issues. Pediatric pharmacology. 2014;11(4):8–15. (In Russ).] doi: 10.15690/pf.v11i4.1057.Ковтун О.В., Романенко В.В. Эффективность пневмококковых конъюгированных вакцин следующего поколения в разных регионах мира // Вопросы современной педиатрии. — 2014. — Т.13. — №1 — С. 18–25. [Kovtun OP, Romanenko VV. Next generation pneumococcal conjugate vaccines efficacy and effectiveness in different regions of the world. Current pediatrics. 2014;13(1):18–25. (In Russ).] doi: 10.15690/vsp.v13i1.908.Ковтун О.В., Романенко В.В. Эффективность пневмококковых конъюгированных вакцин следующего поколения в разных регионах мира // Вопросы современной педиатрии. — 2014. — Т.13. — №1 — С. 18–25. [Kovtun OP, Romanenko VV. Next generation pneumococcal conjugate vaccines efficacy and effectiveness in different regions of the world. Current pediatrics. 2014;13(1):18–25. (In Russ).] doi: 10.15690/vsp.v13i1.908.who.int [Internet]. Estimates of disease burden and costeffectiveness [cited 2017 Dec 24]. Available from: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/en/.who.int [Internet]. Estimates of disease burden and costeffectiveness [cited 2017 Dec 24]. Available from: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/en/.who.int [Internet]. Executive Summary SAGE October 2017. Pneumococcal Conjugate Vaccine Session [cited 2017 Dec 24]. Available from: http://www.who.int/immunization/sage/meetings/2017/october/1_Hosangadi_PCV_ExecutiveSummary_SAGE_PCV_WG_Oct2017.pdf.who.int [Internet]. Executive Summary SAGE October 2017. Pneumococcal Conjugate Vaccine Session [cited 2017 Dec 24]. Available from: http://www.who.int/immunization/sage/meetings/2017/october/1_Hosangadi_PCV_ExecutiveSummary_SAGE_PCV_WG_Oct2017.pdf.Wahl B, O’Brien K, Greenbaum A, Liu L, Chu Y, Majumder A, et al. Global, regional, and national burden of S. pneumoniae and H. influenzae type b in children in the era of conjugate vaccines: updated estimates from 2000–2015. Submitt Publ. 2017.Wahl B, O’Brien K, Greenbaum A, Liu L, Chu Y, Majumder A, et al. Global, regional, and national burden of S. pneumoniae and H. influenzae type b in children in the era of conjugate vaccines: updated estimates from 2000–2015. Submitt Publ. 2017.Пневмококковые вакцины: документ по позиции ВОЗ. Еженедельный эпидемиологический бюллетень. 6 апреля 2012 г. [2012, Pneumococcal Conjugate Vaccine Session. (In Russ).] Доступно по: http://docplayer.ru/44973384-Ezhenedelnyyepidemiologicheskiy-byulleten.html. Ссылка активна на 10.12.2017.Пневмококковые вакцины: документ по позиции ВОЗ. Еженедельный эпидемиологический бюллетень. 6 апреля 2012 г. [2012, Pneumococcal Conjugate Vaccine Session. (In Russ).] Доступно по: http://docplayer.ru/44973384-Ezhenedelnyyepidemiologicheskiy-byulleten.html. Ссылка активна на 10.12.2017.Королёва М.А. Эпидемиологический мониторинг за гнойными бактериальными менингитами в Российской Федерации: Автореф. дис. … канд. мед. наук. — М.; 2014. — 24 с. [Koroleva MA. Epidemiologicheskii monitoring za gnoinymi bakterial’nymi meningitami v Rossiiskoi Federatsii. [dissertation abstract] Moscow; 2014. 24 p. (In Russ).]Королёва М.А. Эпидемиологический мониторинг за гнойными бактериальными менингитами в Российской Федерации: Автореф. дис. … канд. мед. наук. — М.; 2014. — 24 с. [Koroleva MA. Epidemiologicheskii monitoring za gnoinymi bakterial’nymi meningitami v Rossiiskoi Federatsii. [dissertation abstract] Moscow; 2014. 24 p. (In Russ).]Лабораторная диагностика менингококковой инфекции и гнойных бактериальных менингитов. Методические указания. МУК 4.2.1887-04. [Laboratornaya diagnostika meningokokkovoi infektsii i gnoinykh bakterial’nykh meningitov. Metodicheskie ukazaniya. MUK 4.2.1887-04. (In Russ).]Лабораторная диагностика менингококковой инфекции и гнойных бактериальных менингитов. Методические указания. МУК 4.2.1887-04. [Laboratornaya diagnostika meningokokkovoi infektsii i gnoinykh bakterial’nykh meningitov. Metodicheskie ukazaniya. MUK 4.2.1887-04. (In Russ).]Мартынова Г.П., Гульман Л.А., Богвилене Я.А. Клиника, течение и исходы гнойного менингоэнцефалита пневмококковой этиологии у детей // Вопросы современной педиатрии. — 2010. — Т.9. — №4 — С. 110–113. [Martynova GP, Gul’man LA, Bogvilene YaA. Clinical symptoms, course and outcomes of pneumococcal purulent meningoencephalitis in children. Current pediatrics. 2010;9(4):110–113. (In Russ).]Мартынова Г.П., Гульман Л.А., Богвилене Я.А. Клиника, течение и исходы гнойного менингоэнцефалита пневмококковой этиологии у детей // Вопросы современной педиатрии. — 2010. — Т.9. — №4 — С. 110–113. [Martynova GP, Gul’man LA, Bogvilene YaA. Clinical symptoms, course and outcomes of pneumococcal purulent meningoencephalitis in children. Current pediatrics. 2010;9(4):110–113. (In Russ).]Внебольничная пневмония у детей: Клинические рекомендации. — М.: Оригинал-макет; 2015. — 64 с. [Vnebol’nichnaya pnevmoniya u detei: Klinicheskie rekomendatsii. Moscow: Originalmaket; 2015. 64 p. (In Russ).]Внебольничная пневмония у детей: Клинические рекомендации. — М.: Оригинал-макет; 2015. — 64 с. [Vnebol’nichnaya pnevmoniya u detei: Klinicheskie rekomendatsii. Moscow: Originalmaket; 2015. 64 p. (In Russ).]Баранов А.А., Намазова-Баранова Л.С., Маянский Н.А., и др. Роль Streptococcus pneumoniae в структуре бактериальных инфекций у детей, госпитализированных в стационары г. Москвы в 2011–2012 гг. // Педиатрическая фармакология. — 2013. — Т.10. — №5 — С. 6–12. [Baranov AA, Namazova-Baranova LS, Mayanskiy NA, et al. Role of Streptococcus pneumoniae in the structure of bacterial infections in the children hospitalized to inpatient hospitals in Moscow in 2011–2012. Pediatric pharmacology. 2013;10(5):6–12. (In Russ).] doi: 10.15690/pf.v10i5.816. 612. (In Russ).]Баранов А.А., Намазова-Баранова Л.С., Маянский Н.А., и др. Роль Streptococcus pneumoniae в структуре бактериальных инфекций у детей, госпитализированных в стационары г. Москвы в 2011–2012 гг. // Педиатрическая фармакология. — 2013. — Т.10. — №5 — С. 6–12. [Baranov AA, Namazova-Baranova LS, Mayanskiy NA, et al. Role of Streptococcus pneumoniae in the structure of bacterial infections in the children hospitalized to inpatient hospitals in Moscow in 2011–2012. Pediatric pharmacology. 2013;10(5):6–12. (In Russ).] doi: 10.15690/pf.v10i5.816. 612. (In Russ).]Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции. — М.; 2016.— 24 с. [Federal’nye klinicheskie rekomendatsii po vaktsinoprofilaktike pnevmokokkovoi infektsii. Moscow; 2016. 24 p. (In Russ).]Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции. — М.; 2016.— 24 с. [Federal’nye klinicheskie rekomendatsii po vaktsinoprofilaktike pnevmokokkovoi infektsii. Moscow; 2016. 24 p. (In Russ).]Weinberger DM, Trzciński K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5(6):e1000476. doi: 10.1371/journal.ppat.1000476.Weinberger DM, Trzciński K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5(6):e1000476. doi: 10.1371/journal.ppat.1000476.Scott JA, Hall AJ, Dagan R, et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis. 1996;22(6):973–981. doi: 10.1093/clinids/22.6.973.Scott JA, Hall AJ, Dagan R, et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis. 1996;22(6):973–981. doi: 10.1093/clinids/22.6.973.Reinert RR. Pneumococcal conjugate vaccines – a European perspective. Int J Med Microbiol. 2004;294(5):277–294. doi: 10.1016/j.ijmm.2004.04.004.Reinert RR. Pneumococcal conjugate vaccines – a European perspective. Int J Med Microbiol. 2004;294(5):277–294. doi: 10.1016/j.ijmm.2004.04.004.van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One. 2012;7(7):e39150. doi: 10.1371/journal.pone.0039150.van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One. 2012;7(7):e39150. doi: 10.1371/journal.pone.0039150.Greenberg D, Givon-Lavi N, Newman N, et al. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J. 2011;30(3):227–233. doi: 10.1097/INF.0b013e3181f87802.Greenberg D, Givon-Lavi N, Newman N, et al. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J. 2011;30(3):227–233. doi: 10.1097/INF.0b013e3181f87802.Athlin S, Kaltoft M, Slotved HC, et al. Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential. Clin Vaccine Immunol. 2014;21(11):1541–1549. doi: 10.1128/CVI.00259-14.Athlin S, Kaltoft M, Slotved HC, et al. Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential. Clin Vaccine Immunol. 2014;21(11):1541–1549. doi: 10.1128/CVI.00259-14.Kaur R, Czup K, Casey JR, Pichichero ME. Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. BMC Infect Dis. 2014;14:640. doi: 10.1186/s12879-014-0640-y.Kaur R, Czup K, Casey JR, Pichichero ME. Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. BMC Infect Dis. 2014;14:640. doi: 10.1186/s12879-014-0640-y.Coticchia JM, Chen M, Sachdeva L, Mutchnick S. New paradigms in the pathogenesis of otitis media in children. Front Pediatr. 2013;1:52. doi: 10.3389/fped.2013.00052.Coticchia JM, Chen M, Sachdeva L, Mutchnick S. New paradigms in the pathogenesis of otitis media in children. Front Pediatr. 2013;1:52. doi: 10.3389/fped.2013.00052.Rodgers GL, Arguedas A, Cohen R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine. 2009;27(29):3802–3810. doi: 10.1016/j.vaccine.2009.04.021.Rodgers GL, Arguedas A, Cohen R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine. 2009;27(29):3802–3810. doi: 10.1016/j.vaccine.2009.04.021.Fletcher MA, Schmitt HJ, Syrochkina M, Sylvester G. Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology. Eur J Clin Microbiol Infect Dis. 2014;33(6):879–910. doi: 10.1007/s10096-014-2062-6.Fletcher MA, Schmitt HJ, Syrochkina M, Sylvester G. Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology. Eur J Clin Microbiol Infect Dis. 2014;33(6):879–910. doi: 10.1007/s10096-014-2062-6.Tagarro A, Bote P, Sanchez A, et al. Complications of pneumococcal bacteremia after thirteen-valent conjugate vaccine withdrawal. Pediatr Infect Dis J. 2016;35(12):1281–1287. doi: 10.1097/Inf.0000000000001302.Tagarro A, Bote P, Sanchez A, et al. Complications of pneumococcal bacteremia after thirteen-valent conjugate vaccine withdrawal. Pediatr Infect Dis J. 2016;35(12):1281–1287. doi: 10.1097/Inf.0000000000001302.jhsph.edu [Internet]. Pneumococcal Conjugate Vaccine (PCV) Product Assessment. International Vaccine Assess Center, U.S. Centers for Disease Control, University College of London, WHO [cited 2017 Apr 20]. Available from: https://www.jhsph.edu/research/centers-and-institutes/ivac/resources/pcv-product.jhsph.edu [Internet]. Pneumococcal Conjugate Vaccine (PCV) Product Assessment. International Vaccine Assess Center, U.S. Centers for Disease Control, University College of London, WHO [cited 2017 Apr 20]. Available from: https://www.jhsph.edu/research/centers-and-institutes/ivac/resources/pcv-product.Goldblatt D, Southern J, Andrews NJ, et al. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial. Lancet Infect Dis. 2018;18(2):171–179. doi: 10.1016/S1473-3099(17)30654-0.Goldblatt D, Southern J, Andrews NJ, et al. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial. Lancet Infect Dis. 2018;18(2):171–179. doi: 10.1016/S1473-3099(17)30654-0.Брико Н.И., Симонова Е.Г., Костинов М.П., и др. Иммунопрофилактика пневмококковых инфекций. Учебно-методическое пособие для врачей. — М.; 2013. [Briko NI, Simonova EG, Kostinov MP, et al. Immunoprofilaktika pnevmokokkovykh infektsii. Uchebno-metodicheskoe posobie dlya vrachei. Moscow; 2013. (In Russ).]Брико Н.И., Симонова Е.Г., Костинов М.П., и др. Иммунопрофилактика пневмококковых инфекций. Учебно-методическое пособие для врачей. — М.; 2013. [Briko NI, Simonova EG, Kostinov MP, et al. Immunoprofilaktika pnevmokokkovykh infektsii. Uchebno-metodicheskoe posobie dlya vrachei. Moscow; 2013. (In Russ).]Käyhty H, Nurkka А, Soininen А, et al. The immunological basis for immunization series: module 12: pneumococcal vaccines [Internet]. Geneva, Switzerland: WHO; 2009 [cited 2017 Dec 24]. Available from: http://apps.who.int/iris/bitstream/10665/44135/1/9789241598217_eng.pdf.Käyhty H, Nurkka А, Soininen А, et al. The immunological basis for immunization series: module 12: pneumococcal vaccines [Internet]. Geneva, Switzerland: WHO; 2009 [cited 2017 Dec 24]. Available from: http://apps.who.int/iris/bitstream/10665/44135/1/9789241598217_eng.pdf.Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25(19):3816–3826. doi: 10.1016/j.vaccine.2007.01.119.Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25(19):3816–3826. doi: 10.1016/j.vaccine.2007.01.119.Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768. doi: 10.1016/S1473-3099(11)70090-1..Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768. doi: 10.1016/S1473-3099(11)70090-1..Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi: 10.1086/648593.Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi: 10.1086/648593.Nicholls TR, Leach AJ, Morris PS. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: systematic review and meta-analyses of randomized controlled trials. Vaccine. 2016;34(6):703–713. doi: 10.1016/j.vaccine.2015.12.048.Nicholls TR, Leach AJ, Morris PS. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: systematic review and meta-analyses of randomized controlled trials. Vaccine. 2016;34(6):703–713. doi: 10.1016/j.vaccine.2015.12.048.van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56(3):E30–E39. doi: 10.1093/cid/cis922.van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56(3):E30–E39. doi: 10.1093/cid/cis922.Truck J, Jawad S, Goldblatt D, et al. The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy. Pediatr Infect Dis J. 2016;35(7):787–793. doi: 10.1097/Inf.0000000000001180.Truck J, Jawad S, Goldblatt D, et al. The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy. Pediatr Infect Dis J. 2016;35(7):787–793. doi: 10.1097/Inf.0000000000001180.who.int [Internet]. Pneumococcal Conjugate Vaccine Review of Impact Evidence (PRIME). Summary of Findings from Systematic Review. 2017 [cited 2017 Dec 24]. Available from: http://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf.who.int [Internet]. Pneumococcal Conjugate Vaccine Review of Impact Evidence (PRIME). Summary of Findings from Systematic Review. 2017 [cited 2017 Dec 24]. Available from: http://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf.Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15:419. doi: 10.1186/s12879-015-1147-x.Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15:419. doi: 10.1186/s12879-015-1147-x.Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis mediarelated health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121(2):253–260. doi: 10.1542/peds.2007-0619.Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis mediarelated health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121(2):253–260. doi: 10.1542/peds.2007-0619.Ruckinger S, van der Linden M, Reinert RR, et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27(31):4136–4141. doi: 10.1016/j.vaccine.2009.04.057.Ruckinger S, van der Linden M, Reinert RR, et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27(31):4136–4141. doi: 10.1016/j.vaccine.2009.04.057.Bettinger JA, Scheifele DW, Kellner JD, et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine. 2010;28(9):2130–2136. doi: 10.1016/j.vaccine.2009.12.026.Bettinger JA, Scheifele DW, Kellner JD, et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine. 2010;28(9):2130–2136. doi: 10.1016/j.vaccine.2009.12.026.HHS-CDC news: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease US, 1998-2003. Ann Pharmacother. 2005;39(11):1967–1968. doi: 10.1345/aph.1N096.HHS-CDC news: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease US, 1998-2003. Ann Pharmacother. 2005;39(11):1967–1968. doi: 10.1345/aph.1N096.Ruiz-Contreras J, Picazo J, Casado-Flores J, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Vaccine. 2017;35(35 Pt B):4646–4651. doi: 10.1016/j.vaccine.2017.06.070.Ruiz-Contreras J, Picazo J, Casado-Flores J, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Vaccine. 2017;35(35 Pt B):4646–4651. doi: 10.1016/j.vaccine.2017.06.070.Инструкция по применению вакцины Превенар 13. ЛП-000798-041016. [Instruktsiya po primeneniyu vaktsiny Prevenar 13. LP-000798-041016. (In Russ).]Инструкция по применению вакцины Превенар 13. ЛП-000798-041016. [Instruktsiya po primeneniyu vaktsiny Prevenar 13. LP-000798-041016. (In Russ).]Инструкция по применению вакцины Синфлорикс. ЛП 001412-220416. [Instruktsiya po primeneniyu vaktsiny Sinfloriks. LP 001412-220416. (In Russ).]Инструкция по применению вакцины Синфлорикс. ЛП 001412-220416. [Instruktsiya po primeneniyu vaktsiny Sinfloriks. LP 001412-220416. (In Russ).]Kaplan SL, Center KJ, Barson WJ, et al. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis. 2015;60(9):1339–1345. doi: 10.1093/cid/civ067.Kaplan SL, Center KJ, Barson WJ, et al. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis. 2015;60(9):1339–1345. doi: 10.1093/cid/civ067.Cho YC, Chiu NC, Lu CY, et al. Redistribution of Streptococcus pneumoniae serotypes after nationwide 13-valent pneumococcal conjugate vaccine program in children in Northern Taiwan. Pediatr Infect Dis J. 2017;36(12):334–340. doi: 10.1097/INF.0000000000001664.Cho YC, Chiu NC, Lu CY, et al. Redistribution of Streptococcus pneumoniae serotypes after nationwide 13-valent pneumococcal conjugate vaccine program in children in Northern Taiwan. Pediatr Infect Dis J. 2017;36(12):334–340. doi: 10.1097/INF.0000000000001664.Nakano S, Fujisawa T, Ito Y, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and noninvasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014. Vaccine. 2016;34(1):67–76. doi: 10.1016/j.vaccine.2015.11.015.Nakano S, Fujisawa T, Ito Y, et al. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and noninvasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014. Vaccine. 2016;34(1):67–76. doi: 10.1016/j.vaccine.2015.11.015.Kuttel MM, Jackson GE, Mafata M, Ravenscroft N. Capsular polysaccharide conformations in pneumococcal serotypes 19F and 19A. Carbohydr Res. 2015;406:27–33. doi: 10.1016/j.carres.2014.12.013.Kuttel MM, Jackson GE, Mafata M, Ravenscroft N. Capsular polysaccharide conformations in pneumococcal serotypes 19F and 19A. Carbohydr Res. 2015;406:27–33. doi: 10.1016/j.carres.2014.12.013.Isturiz R, Sings HL, Hilton B, et al. Streptococcus pneumonia serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16(10):1007–1027. doi: 10.1080/14760584.2017.1362339.Isturiz R, Sings HL, Hilton B, et al. Streptococcus pneumonia serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16(10):1007–1027. doi: 10.1080/14760584.2017.1362339.esr.cri.nz [Internet]. New Zealand Public Health Surveillance. Invasive Pneumococcal Disease Reports, 2016 [cited 2017 Dec 24]. Available from: https://surv.esr.cri.nz/surveillance/IPD.php.esr.cri.nz [Internet]. New Zealand Public Health Surveillance. Invasive Pneumococcal Disease Reports, 2016 [cited 2017 Dec 24]. Available from: https://surv.esr.cri.nz/surveillance/IPD.php.Jaakola S, Lyytikäinen O, Rimhanen-Finne R, et al, editors. Infectious Diseases in Finland 2015 [Internet]. National Institute for Health and Welfare, Report 15/2016 [cited 2017 Dec 24]. Available from: https://www.julkari.fi/bitstream/handle/10024/131379/URN_ISBN_978-952-302-710-7.pdf?sequence=1.Jaakola S, Lyytikäinen O, Rimhanen-Finne R, et al, editors. Infectious Diseases in Finland 2015 [Internet]. National Institute for Health and Welfare, Report 15/2016 [cited 2017 Dec 24]. Available from: https://www.julkari.fi/bitstream/handle/10024/131379/URN_ISBN_978-952-302-710-7.pdf?sequence=1.thl.fi [Internet]. National Institute for health and welfare. Incidence of invasive pneumococcal disease in Finland [cited 2017 Dec 24]. Available from: https://www.thl.fi/fi/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoringthe-population-effectiveness-of-pneumococcal-conjugatevaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland.thl.fi [Internet]. National Institute for health and welfare. Incidence of invasive pneumococcal disease in Finland [cited 2017 Dec 24]. Available from: https://www.thl.fi/fi/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoringthe-population-effectiveness-of-pneumococcal-conjugatevaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland.Jokinen J, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children — a population-based study. PLoS One. 2015;10(3):e0120290. doi: 10.1371/journal.pone.0120290.Jokinen J, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children — a population-based study. PLoS One. 2015;10(3):e0120290. doi: 10.1371/journal.pone.0120290.Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Heal. 2014;2(7):e397–e405. doi: 10.1016/S2214-109X(14)70224-4.Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Heal. 2014;2(7):e397–e405. doi: 10.1016/S2214-109X(14)70224-4.Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, et al. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumonia in children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep. 2016;6(1):23809. doi: 10.1038/srep23809.Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, et al. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumonia in children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep. 2016;6(1):23809. doi: 10.1038/srep23809.Ppaho.org [Internet]. PAHO and OPAS/OMS. SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables de Neumonias y Meningitis Bacterianas) [cited 2017 Dec 24]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=5536%3A2011-sireva-ii&catid=1591%3Aabout&Itemid=3966&lang=pt.Ppaho.org [Internet]. PAHO and OPAS/OMS. SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables de Neumonias y Meningitis Bacterianas) [cited 2017 Dec 24]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=5536%3A2011-sireva-ii&catid=1591%3Aabout&Itemid=3966&lang=pt.Harboe Z, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–1073. doi: 10.1093/cid/ciu524.Harboe Z, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–1073. doi: 10.1093/cid/ciu524.Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543. doi: 10.1016/S1473-3099(15)70044-7.Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543. doi: 10.1016/S1473-3099(15)70044-7.jhsph.edu [Internet]. Gap Analysis of PCV Impact Evaluations in Settings of Routine Use. International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health [cited 2017 Dec 24]. Available from: https://www.jhsph.edu/research/centers-andinstitutes/ivac/resources/RVImpactGapAnalysis_FEB2017_FINAL_public.pdf.jhsph.edu [Internet]. Gap Analysis of PCV Impact Evaluations in Settings of Routine Use. International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health [cited 2017 Dec 24]. Available from: https://www.jhsph.edu/research/centers-andinstitutes/ivac/resources/RVImpactGapAnalysis_FEB2017_FINAL_public.pdf.Lyu S, Yao KH, Dong F, et al. Vaccine serotypes of Streptococcus pneumoniae with high-level antibiotic resistance isolated more frequently seven years after the licensure of PCV7 in Beijing. Pediatr Infect Dis J. 2016;35(3):316–321. doi: 10.1097/INF.0000000000001000.Lyu S, Yao KH, Dong F, et al. Vaccine serotypes of Streptococcus pneumoniae with high-level antibiotic resistance isolated more frequently seven years after the licensure of PCV7 in Beijing. Pediatr Infect Dis J. 2016;35(3):316–321. doi: 10.1097/INF.0000000000001000.Ochoa-Gondar O, Gómez-Bertomeu F, Vila-Córcoles A, et al. [Prevalence of serotypes causing invasive pneumococcal disease in the region of Tarragona, Spain, 2006-2009: vaccine-serotype coverage for the distinct antipneumococcal vaccine formulations. (In Spanish).] Rev Esp Quimioter. 2015;28(1):29–35.Ochoa-Gondar O, Gómez-Bertomeu F, Vila-Córcoles A, et al. [Prevalence of serotypes causing invasive pneumococcal disease in the region of Tarragona, Spain, 2006-2009: vaccine-serotype coverage for the distinct antipneumococcal vaccine formulations. (In Spanish).] Rev Esp Quimioter. 2015;28(1):29–35.Phongsamart W, Srifeungfung S, Chatsuwan T, et al. Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009–2012. Hum Vaccin Immunother. 2014;10(7):1866–1873. doi: 10.4161/hv.28675.Phongsamart W, Srifeungfung S, Chatsuwan T, et al. Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009–2012. Hum Vaccin Immunother. 2014;10(7):1866–1873. doi: 10.4161/hv.28675.Pan F, Han L, Huang W, et al. Serotype distribution, antimicrobial susceptibility, and molecular epidemiology of Streptococcus pneumoniae isolated from children in Shanghai, China. PLoS One. 2015;10(11):e0142892. doi: 10.1371/journal.pone.0142892.Pan F, Han L, Huang W, et al. Serotype distribution, antimicrobial susceptibility, and molecular epidemiology of Streptococcus pneumoniae isolated from children in Shanghai, China. PLoS One. 2015;10(11):e0142892. doi: 10.1371/journal.pone.0142892.Al-Sheikh YA, K Gowda L, Mohammed Ali MM, et al. Distribution of serotypes and antibiotic susceptibility patterns among invasive pneumococcal diseases in Saudi Arabia. Ann Lab Med. 2014;34(3):210–215. doi: 10.3343/alm.2014.34.3.210.Al-Sheikh YA, K Gowda L, Mohammed Ali MM, et al. Distribution of serotypes and antibiotic susceptibility patterns among invasive pneumococcal diseases in Saudi Arabia. Ann Lab Med. 2014;34(3):210–215. doi: 10.3343/alm.2014.34.3.210.Zhao C, Zhang F, Chu Y, et al. Phenotypic and genotypic characteristic of invasive pneumococcal isolates from both children and adult patients from a multicenter surveillance in China 2005-2011. PLoS One. 2013;8(12):e82361. doi: 10.1371/journal. pone.0082361.Zhao C, Zhang F, Chu Y, et al. Phenotypic and genotypic characteristic of invasive pneumococcal isolates from both children and adult patients from a multicenter surveillance in China 2005-2011. PLoS One. 2013;8(12):e82361. doi: 10.1371/journal. pone.0082361.Park M, Kim HS, Shin KS, et al. Changes in the incidence of Streptococcus pneumoniae bacteremia and its serotypes over 10 years in one hospital in South Korea. Vaccine. 2014;32(48):6403–6407. doi: 10.1016/j.vaccine.2014.09.062.6403.Park M, Kim HS, Shin KS, et al. Changes in the incidence of Streptococcus pneumoniae bacteremia and its serotypes over 10 years in one hospital in South Korea. Vaccine. 2014;32(48):6403–6407. doi: 10.1016/j.vaccine.2014.09.062.6403.paho.org [Internet]. Pan American Health Organization, New Vaccines Map [cited 2017 Dec 24]. Available from: http://www. paho.org/hq/index.php?option=com_content&view=article&id=1938&Itemid=1678&lang=en.paho.org [Internet]. Pan American Health Organization, New Vaccines Map [cited 2017 Dec 24]. Available from: http://www. paho.org/hq/index.php?option=com_content&view=article&id=1938&Itemid=1678&lang=en.Приказ Минздрава РФ №125н от 21.03.2014 г. «Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям». [Order of the Ministry of Health of the Russian Federation №125n “Ob utverzhdenii natsional’nogo kalendarya profilakticheskikh privivok i kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam” dated March 21 2014. (In Russ).]Приказ Минздрава РФ №125н от 21.03.2014 г. «Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям». [Order of the Ministry of Health of the Russian Federation №125n “Ob utverzhdenii natsional’nogo kalendarya profilakticheskikh privivok i kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam” dated March 21 2014. (In Russ).]Резолюция заседания Общественного Координационного Совета по пневмококковой инфекции и вакцинации в России // Педиатрическая фармакология. — 2016. — Т.13. — №1 — С. 76–79. [Resolution of the meeting of the Public Coordination Council on Pneumococcal Infection and Vaccination in Russia. Pediatric pharmacology. 2016;13(1):76–79. (In Russ).] doi: 10.15690/pf.v13i1.1522.Резолюция заседания Общественного Координационного Совета по пневмококковой инфекции и вакцинации в России // Педиатрическая фармакология. — 2016. — Т.13. — №1 — С. 76–79. [Resolution of the meeting of the Public Coordination Council on Pneumococcal Infection and Vaccination in Russia. Pediatric pharmacology. 2016;13(1):76–79. (In Russ).] doi: 10.15690/pf.v13i1.1522.Лобзин Ю.В., Сидоренко С.В., Харит С.М., и др. Серотипы Streptococcus pneumoniae, вызывающие ведущие нозологические формы пневмококковых инфекций // Журнал инфектологии. — 2013. — Т.5. — №4 — С. 36–42. [Lobzin YuV, Sidorenko SV, Kharit SM, et al. Serotypes of Streptococcus pneumoniae causing major pneumococcal infections. Zhurnal infektologii. 2013;5(4):36–42. (In Russ).]Лобзин Ю.В., Сидоренко С.В., Харит С.М., и др. Серотипы Streptococcus pneumoniae, вызывающие ведущие нозологические формы пневмококковых инфекций // Журнал инфектологии. — 2013. — Т.5. — №4 — С. 36–42. [Lobzin YuV, Sidorenko SV, Kharit SM, et al. Serotypes of Streptococcus pneumoniae causing major pneumococcal infections. Zhurnal infektologii. 2013;5(4):36–42. (In Russ).]Белошицкий Г.В. Серотиповая характеристика штаммов S. pneumoniae в Москве // Эпидемиология и вакцинопрофилактика. — 2014. — №1 — С. 90–97. [Beloshitskii GV. Serotipovaya kharakteristika shtammov S. pneumoniae v Moskve. Epidemiologiya i vaktsinoprofilaktika. 2014;(1):90–97. (In Russ).]Белошицкий Г.В. Серотиповая характеристика штаммов S. pneumoniae в Москве // Эпидемиология и вакцинопрофилактика. — 2014. — №1 — С. 90–97. [Beloshitskii GV. Serotipovaya kharakteristika shtammov S. pneumoniae v Moskve. Epidemiologiya i vaktsinoprofilaktika. 2014;(1):90–97. (In Russ).]Козлов Р.С., Кречикова О.И., Муравьев А.А., и др. Результаты исследования распространенности в России внебольничной пневмонии и острого среднего отита у детей в возрасте до 5 лет (PAPIRUS). Роль S. pneumoniae и H. influenzae в этиологии данных заболеваний // Клиническая микробиология и антимикробная химиотерапия. — 2013. — Т.15. — №4 — 246–260. [Kozlov RS, Krechikova OI, Muravyev AA, et al. РIncidence of communityacquired pneumonia and acute otitis media in children 0–5 years in Russia and role of S. pneumoniae or H. influenzae in the etiology of the diseases. Clinical microbiology and antimicrobial chemotherapy. 2013;15(4):246–260. (In Russ).]Козлов Р.С., Кречикова О.И., Муравьев А.А., и др. Результаты исследования распространенности в России внебольничной пневмонии и острого среднего отита у детей в возрасте до 5 лет (PAPIRUS). Роль S. pneumoniae и H. influenzae в этиологии данных заболеваний // Клиническая микробиология и антимикробная химиотерапия. — 2013. — Т.15. — №4 — 246–260. [Kozlov RS, Krechikova OI, Muravyev AA, et al. РIncidence of communityacquired pneumonia and acute otitis media in children 0–5 years in Russia and role of S. pneumoniae or H. influenzae in the etiology of the diseases. Clinical microbiology and antimicrobial chemotherapy. 2013;15(4):246–260. (In Russ).]Mayanskiy N, Alyabieva N, Ponomarenko O, et al. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumonia circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis. 2014;20:58–62. doi: 10.1016/j.ijid.2013.11.005.Mayanskiy N, Alyabieva N, Ponomarenko O, et al. Serotypes and antibiotic resistance of non-invasive Streptococcus pneumonia circulating in pediatric hospitals in Moscow, Russia. Int J Infect Dis. 2014;20:58–62. doi: 10.1016/j.ijid.2013.11.005.Tatochenko V, Sidorenko S, Namazova-Baranova L, et al. Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program. Expert Rev Vaccines. 2014;13(2):257–264. doi: 10.1586/14760584.2013.871205.Tatochenko V, Sidorenko S, Namazova-Baranova L, et al. Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program. Expert Rev Vaccines. 2014;13(2):257–264. doi: 10.1586/14760584.2013.871205.Alyabyeva N, Mayanskiy N, Ponomarenko O, et al. Serotype distribution and antibiotic resistance of Streptococcus pneumonia isolated from children with acute otitis media in Russia. In: Poster ESPID, 2012; Thessaloniki, Greece. p. 431.Alyabyeva N, Mayanskiy N, Ponomarenko O, et al. Serotype distribution and antibiotic resistance of Streptococcus pneumonia isolated from children with acute otitis media in Russia. In: Poster ESPID, 2012; Thessaloniki, Greece. p. 431.Kozlov R, Chagaryan A, Kozlova L. Penicicllin resistance of predominant serotypes of Streptococcus pneumoniae in children of the Russian Federation. In: Poster ECCMID, 2012. Proceedings of the 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); 2011 Nov 16–19; Melbourne, Australia. Abstract 26.Kozlov R, Chagaryan A, Kozlova L. Penicicllin resistance of predominant serotypes of Streptococcus pneumoniae in children of the Russian Federation. In: Poster ECCMID, 2012. Proceedings of the 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); 2011 Nov 16–19; Melbourne, Australia. Abstract 26.Естественное движение населения в разрезе субъектов РФ за январь-декабрь 2016 года. [Estestvennoe dvizhenie naseleniya v razreze sub”ektov RF za yanvar’-dekabr’ 2016 goda. (In Russ).]Естественное движение населения в разрезе субъектов РФ за январь-декабрь 2016 года. [Estestvennoe dvizhenie naseleniya v razreze sub”ektov RF za yanvar’-dekabr’ 2016 goda. (In Russ).]Естественное движение населения в разрезе субъектов РФ за январь-февраль 2017 года. [Estestvennoe dvizhenie naseleniya v razreze sub”ektov RF za yanvar’-fevral’ 2017 goda. (In Russ).]Естественное движение населения в разрезе субъектов РФ за январь-февраль 2017 года. [Estestvennoe dvizhenie naseleniya v razreze sub”ektov RF za yanvar’-fevral’ 2017 goda. (In Russ).]Dagan R, Pelton S, Bakaletz L. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016;16(4):480–492. doi: 10.1016/S1473-3099(15)00549-6.Dagan R, Pelton S, Bakaletz L. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016;16(4):480–492. doi: 10.1016/S1473-3099(15)00549-6.Dagan R, Ben-Shimol S, Leibovitz E. Implementation of PCV7/PCV13 in Israel had a signifi cant impact on both pneumococcal and non-pneumococcal complex otitis media rates. Poster Abstract Session: Adult and Pediatric Vaccines. Proceedings of 2014 Meeting of the Infectious Diseases Society of America; 2014 Oct 10; Philadelphia, PA, USA.Dagan R, Ben-Shimol S, Leibovitz E. Implementation of PCV7/PCV13 in Israel had a signifi cant impact on both pneumococcal and non-pneumococcal complex otitis media rates. Poster Abstract Session: Adult and Pediatric Vaccines. Proceedings of 2014 Meeting of the Infectious Diseases Society of America; 2014 Oct 10; Philadelphia, PA, USA.

The authors declare that there are no conflicts of interest present.